Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques
Launched by SPECTRUM HEALTH HOSPITALS · Sep 24, 2012
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
This study is being performed to characterize the composition and morphologic characteristics of atherosclerotic coronary artery plaques with intra-coronary near-infrared spectroscopy and intravascular ultrasound in patients undergoing percutaneous coronary intervention.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject is at \> 18 years of age
- • 2. Subject presents to the catheterization laboratory to undergo clinically-indicated, invasive coronary angiography
- • 3. Subject is willing and able to provide informed written consent
- • 4. Subject is found to have ≥ 1 severe coronary artery stenosis by invasive angiography and percutaneous coronary intervention is planned for definitive treatment or found to have ≥ 1 intermediate coronary artery stenosis and IVUS planned for lesion assessment
- • 5. Coronary anatomy is deemed suitable for combined NIRS-IVUS by the interventional cardiologist performing invasive angiography and intervention
- Exclusion Criteria:
- • 1. Subject is pregnant or suspected to be pregnant
- • 2. Subject is unable to provide informed consent
- • 3. Subject has coronary artery anatomy deemed by interventionalist as unsuitable for NIRS-IVUS
About Spectrum Health Hospitals
Spectrum Health Hospitals is a leading healthcare provider dedicated to delivering high-quality patient care and advancing medical research through innovative clinical trials. As a part of a comprehensive health system, Spectrum Health Hospitals integrates cutting-edge technology and evidence-based practices to enhance patient outcomes and contribute to the broader medical community. With a commitment to ethical standards and patient safety, Spectrum Health Hospitals actively engages in diverse clinical research initiatives, fostering collaboration among healthcare professionals, researchers, and participants to drive advancements in treatment and therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grand Rapids, Michigan, United States
Patients applied
Trial Officials
Ryan D Madder, MD
Principal Investigator
Spectrum Health Hospitals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials